My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista Española de Cirugía Oral y Maxilofacial
On-line version ISSN 2173-9161Print version ISSN 1130-0558
Abstract
DELGADO SANCHEZ, M. et al. Efficacy of single drug therapy with piperacillin-tazobactam in infections of the maxillofacial area. Rev Esp Cirug Oral y Maxilofac [online]. 2004, vol.26, n.2, pp.97-106. ISSN 2173-9161.
Abstract: Objective: Maxillofacial infections are a frequent cause for consulting maxillofacial surgeons. Dental problems are the most frequent source of infections, these being typically polymicrobial. For these reasons, safety and efficacy of piperacillin/tazobactam in maxillofacial infections were evaluated in this study. Design: Multicenter and prospective study in which seventy-nine patients with maxillofacial infections were treated with piperacillin/tazobactam. Results: 97.5% of the evaluable patients were clinically cured or improved and the bacteriologic eradication rate was 96.2%. Five out of 79 (6.3%) had an adverse event (two dyspepsia, two dizziness and one phlebitis). No deaths were attributable to the study drug. Conclusions: Piperacillin/tazobactam is a good single drug treatment choice for maxillofacial infections.
Keywords : maxillofacial infections; piperacillin-tazobactam; clinical efficacy; safety.